Atypical role of sprouty in colorectal cancer: sprouty repression inhibits epithelial–mesenchymal transition

**INTRODUCTION**
Sprouty (SPRY) is an intracellular regulator of receptor tyrosine kinase signaling involved in growth, differentiation and tumorigenesis. Four family members of SPRY (SPRY1–4) have been identified. SPRY2 appears to be ubiquitously expressed, whereas other family members show organ and tissue specificity. Experimental evidence demonstrate that SPRY specifically inhibits activation of extracellular-regulated kinase in response to nerve growth factor, platelet-derived growth factor (PDGF), vascular endothelial growth factor, brain derived neutrotrophic factor, glial cell line-derived neutrotrophic factor and fibroblast growth factor. On the contrary, mitogen-activated protein kinase activation is not always inhibited by SPRY. Surprisingly, in some instances, SPRY1 and SPRY2 not only failed to suppress epidermal growth factor-induced mitogen-activated protein kinase activation but also enhanced activation of this pathway.

Expression of SPRY1 and SPRY2 is reduced in breast, prostate, lung and liver carcinoma, suggesting a tumor-suppressor role of SPRY in cancer. Role of SPRY in colorectal cancer (CRC) is still evolving. We demonstrated increased SPRY2 protein expression in human CRC. Likewise, high expression of SPRY2 in human CRC and its association with poor patient survival has been recently reported. On the contrary, other investigators noted reduced SPRY2 transcripts in intestinal tumors. Interestingly, a meta-analysis at the oncome database concluded that SPRY2 expression is higher in CRC tumors than in other cancers. An inverse correlation of SPRY2 with E-cadherin and increased immunoreactive SPRY2 in undifferentiated high-grade tumors and at the invasive front of low-grade carcinomas implicated SPRY2 in tumor metastasis. The study of gene expression signatures in CRC with or without KRAS mutations also revealed upregulation of SPRY2 in KRAS mutant tumors. Mechanistically, we established that TAT-SPRY2 protein transduction or SPRY2 CDNA stable transfection significantly increased tumorigenicity and metastatic potential of colon cancer cells via elevated c-Met expression.

Despite these observations, molecular regulation of epithelial-to-mesenchymal transition (EMT) by SPRY2 is never investigated in CRC. In this study, we provided the experimental evidence that SPRY2 regulates miR-194. SPRY2 and miR-194-dependent suppression of AKT2 and other repressors of E-cadherin may account for upregulation of E-cadherin and inhibition of cancer cell migration and invasion. Underscoring the biological relevance of these observations, recombination of floxed SPRY1 and SPRY2 alleles in mouse embryonic fibroblasts (MEFs) resulted in increased expression of epithelial markers and decreased cell migration. Further, expression profile analysis in human CRC revealed increased SPRY1 and SPRY2 transcripts and an inverse expression pattern between AKT2 and E-cadherin. Together, this study indicates that SPRY is a target of therapeutic intervention in CRC metastasis.

**RESULTS**
SPRY is upregulated in human CRC and positively regulates metastatic potential of colon cancer cells
We evaluated relative expression of SPRY1 and SPRY2 mRNA transcripts in human colon cancer tissues and adjacent controls by

---

1. Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Missouri, Columbia, MO, USA; 2. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA; 3. Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL, USA; 4. Molecular Cytology Core, University of Missouri, Columbia, MO, USA and 5. Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO, USA. Correspondence: Professor S Khare, Department of Internal Medicine, University of Missouri, 1 Hospital Drive, Columbia, MO 65212, USA. E-mail: khares@health.missouri.edu

Received 6 January 2015; revised 7 August 2015; accepted 28 August 2015; published online 5 October 2015
utilizing a colon cancer cDNA array. Majority of the cancer samples demonstrated upregulation of SPRY1 and SPRY2 transcripts as compared with adjacent controls (Figure 1a). To determine whether SPRY2 regulates EMT in colon cancer cells, we selected HCT116 and SW480 human colon cancer cell lines that contained different levels of endogenous SPRY2 protein expression (Figure 1b). SPRY2 downregulation by siRNA resulted in transdifferentiation of cancer cells and significantly shifted cell morphology from fibroblastoid or more-elongated fibroblast-like shape to epithelial-like shape in both cell lines irrespective of the
endogenous level of SPRY2 expression (Figure 1b). In Boyden chambers, SPRY2 suppression significantly decreased cell migratory and invasive capabilities of HCT116 cells (Figure 1c). Similarly, an inhibition in cell migration and invasion was also observed in SPRY2-downregulated SW480 cells (Figure 1c). Multiple studies have shown that E-cadherin is intricately involved in retaining cell-to-cell contacts and inhibiting cell motility in cancer cells.\textsuperscript{15} To determine whether E-cadherin was affected by SPRY2, we assessed E-cadherin protein and mRNA expression in SPRY2-downregulated cancer cells. Suppression of SPRY2 significantly increased E-cadherin protein (1.7- and 2.6-fold in HCT116 and SW480 cells, respectively, \(P < 0.05\)) and mRNA expression (2- and 2.5-fold in HCT116 and SW480 cells, respectively, \(P < 0.05\)) in both cell lines (Figure 1d). Repression of E-cadherin in epithelial cells is mediated by EMT markers/EMT-inducing transcription factors SNAIL1, SLUG (SNAIL2), TWIST1 and ZEB1/2.\textsuperscript{12,13} SPRY2 suppression significantly decreased SNAIL2 and ZEB1 in HCT116 cells, whereas SNAIL1, TWIST1 and ZEB2 were not significantly changed. However, in SW480 cells, SPRY2 suppression resulted in reduced SNAIL1, ZEB1/2 and TWIST1 expression, whereas SNAIL2 was unaffected (Figure 1e). Collectively, results indicate that SPRY2 may affect CRC metastasis in a positive manner and reduction of SPRY2 inhibits EMT in colon cancer cells.

Inverse correlation of miR-194-5p with SPRY2 expression
Various MicroRNAs (miRs) control EMT and cancer cell migration and invasion during tumor metastasis.\textsuperscript{14} We hypothesized that SPRY2 expression differentially regulate oncogenic and tumor-suppressor miRs and their target genes during CRC metastasis. Preliminary studies were conducted to determine the effect of SPRY2 suppression on the miR expression profile. HCT116 cells were stably transfected with three different SPRY2 shRNAs (shRNA 7522, shRNA 589, shRNA 588) using lentiviral expression system. Because of the random integration of the lentivirus into the host genome, varying levels of SPRY2 gene knockdown was expected in puromycin-resistant colonies. Colonies infected with shRNA 7522 demonstrated maximum suppression of SPRY2 followed by shRNAs 589 and 588 (Supplementary Figure S1). Maximal suppression of SPRY2 in clone 7522 resulted in a more than twofold upregulation of miR-194-5p, -4423 and -3925 and downregulation of miR-21 and -491 (corresponding to at least \(\pm 1.0 \log \) fold change) (Supplementary Table 1). Relatively lower suppression of SPRY2 in clone 589 caused lesser fold changes in the expression levels of above mentioned miRs. Furthermore, miRs were least affected, except miR-21, if SPRY2 was minimally suppressed (clone 588). These results demonstrate that a differential expression of certain miRs, depending upon the level of SPRY2 suppression, could be achieved in colon cancer cells. The role of oncogenic miR-21 in cancer including CRC is well established and has been studied extensively.\textsuperscript{15} We focused our investigation on miR-194, because this is mainly expressed in the gastrointestinal tract.\textsuperscript{16} The role of miR-4423, – 3925 and – 491 in CRC is not clearly understood at this point of investigation.

Mir-194 precursor is processed into miR-194-5p and miR-194-3p. Mir-194-5p is the major mature form of miR-194. To further confirm that SPRY2 suppression affects miR-194-5p expression levels, HCT116 and SW480 cells were transiently transfected with SPRY2 siRNA. MiR-194-5p levels were significantly upregulated (threefold, \(P < 0.05\)) in HCT116 and SW480 cells (Figure 2a). Further, SPRY2 downregulation had no significant effect on miR-194-3p expression levels in cancer cells (Supplementary Figure S2). We then investigated endogenous contents of miR-194-5p in three different colon cancer cell lines that express different levels of SPRY2. HCT116 and SW480 cancer cells have significantly lower contents of miR-194-5p than HT29 cells (Supplementary Figure S3). Therefore, in subsequent experiments HCT116 and SW480 cells were used for miR-194 mimic transfection, whereas HT29 cells were used for miR-194 inhibitor experiments. Collectively, above results demonstrate that SPRY2 suppression by two different methods significantly upregulated miR-194-5p contents of colon cancer cells.

Figure 1. SPRY1 and SPRY2 expression is upregulated in human CRC and silencing of SPRY2 suppresses EMT in colon cancer cells. (a) SPRY1 and SPRY2 mRNA levels in a human colon adenocarcinoma cDNA array containing 24 matched pairs (48 samples) covering 24 normal and 24 adenocarcinomas. Expression levels are shown relative to matched normal samples from all 24 patients. (b) Morphological changes in SPRY2 siRNA (100 nm, 96 h) transfected HCT116 and SW480 cells. A representative western blotting with quantification of SPRY2 expression in control scrambled siRNA or siRNA SPRY2-transfected cells, size bar = 50 \(\mu m\). Results were confirmed by repeating the experiment seven times (\(n = 7\)). (c) SPRY2 suppression decreases cell migration and invasion of HCT116 and SW480 cells in a trans-well migration and invasion assay. Average number of cells from three random microscopic high power (HP) fields per insert were counted, size bar = 200 \(\mu m\). Results from three experiments (\(n = 3\)) were analyzed, and data are expressed as mean \(\pm\) s.d., \(P < 0.05\). Western blotting represents relative SPRY2 expression in HCT116 and SW480 cells used in migration and invasion assays. (d) SPRY2 suppression increases E-cadherin protein and mRNA expression. A representative western blotting with quantification of SPRY2 and E-cadherin protein in control scrambled siRNA or siRNA SPRY2-transfected cells. Results were confirmed by repeating the experiment five times (\(n = 5\)). SPRY2 and E-cadherin mRNA expression (mean \(\pm\) s.d., \(n = 5\)), \(^*P < 0.05\) in HCT116 and SW480 cells transfected with control scrambled siRNA or siRNA SPRY2. (e) SPRY2 suppression decreases EMT markers (EMT-inducing transcription factors); miR levels were determined in HCT116 and SW480 cells transfected with control scrambled siRNA or siRNA SPRY2 siRNA. Results are mean \(\pm\) s.d., (\(n = 5\)), \(^*P < 0.05\).
abilities of HCT116 and SW480 cells (Figure 2f). As expected, miR-194 mimic transfection also delayed cell migration in SW480 cells in a wound-healing assay (Supplementary Figure S5). In wound-healing assay, HCT116 cells are not viable in a 6-day-long experiment with low serum-containing medium. In summary, studies demonstrate a significant role of miR-194 in negative regulation of EMT in CRC.

AKT2 is a direct target of miR-194

More often, miRs negatively regulate gene expression at the postranscriptional level. The binding of miRs to complimentary sites in the 3’ untranslated regions (UTRs) of mRNA sequences cause either degradation of mRNA or inhibition of translation. Several genes of interest were predicted by the search programs of miRanda and TargetScan, and the effect of miR-194 on...
Talin2, SOX5, Musashi, AKT2, Rac1, HBEGF and IGF-1 R was tested by quantitative real-time (RT–PCR) and western blotting (Supplementary Figure S6). Majority of the targets were not affected; however, Talin-2 protein was downregulated. Further, Rac1 protein in HCT116 cells (Supplementary Figure S6A) and IGF-1 R mRNA in SW480 cells (Supplementary Figure S6B) showed increased steady-state levels, reflecting either indirect effects or atypical miR-target interactions. We observed a consistent significant downregulation of AKT2 expression (>80%, P < 0.05) with predicted binding to 3′ (picTar, miRanda and TargetScan). A significant downregulation of EMT was also observed in miR-194 transfection HCT116 (Figure 4a) and SW480 (Figure 4b) cells. Cancer cells were transfected with miR-control or miR-194 mimics, and transfection was confirmed by increased miR-194 levels as assessed by RT–PCR (Supplementary Figure S9). Following the miR-194 transfection, cancer cells exhibit more E-cadherin immunoreactivity compared with control-transfected cells. Control cells show diffuse E-cadherin distribution throughout the cell. In miR-194-transfected cells, the immunoreactive E-cadherin appears in small vesicles that have a tendency to concentrate in the cell periphery in the area of plasma membrane. Furthermore, AKT2 immunoreactivity declined when cells were transfected with miR-194 as compared with control. AKT2-dependent oncogenic pathways can be activated through its translocation to the nucleus. However, miR-194 transfection moderately increased the association of AKT2 with E-cadherin on the cell membrane, but no nuclear translocation of AKT2 was noted. Collectively, data indicate that miR-194 may inhibit EMT by increasing expression and membrane localization of E-cadherin and partial association of E-cadherin with AKT2.

Inverse expression pattern of AKT2 and E-cadherin in human colon cancer
We then raised the question whether AKT2 and E-cadherin expression are related in human CRC and evaluated immunohistochemical staining of E-cadherin and weak cytosolic AKT2 expression in tumors was noted (Figure 4c). Further, strong membranous staining of E-cadherin and weak cytosolic AKT2 expression was found in adjacent normal tissues. However, a significant decrease in membranous E-cadherin and increase in nuclear AKT2 staining was noted in human adenocarcinomas (Figure 4d). Statistical analysis also revealed an inverse expression pattern between AKT2 and E-cadherin in human colon cancer tissues (Figure 4e).

Figure 2. Increased miR-194 levels in SPRY2-downregulated cancer cells and miR-194 transfection suppresses EMT. (a) Cancer cells were transfected with scrambled siRNA or SPRY2 siRNA. SPRY2 suppression significantly increases miR-194-5p levels in HCT116 and SW480 cells. Results are mean ± s.d. (n = 5), *P < 0.05. (b) Morphological changes in miR-194 mimic (100 nm, 96 h) transfected HCT116 and SW480 cells. The bar diagram represents relative miRNA-194 contents of miR-control or miR-194 mimic-transfected cells, size bar = 50 μm. Results are mean ± s.d. (n = 5), *P < 0.05. (c) miR-194 alters E-cadherin expression; a representative western blotting and quantification of E-cadherin protein in miR-control or miR-194 mimics (100 nm, 96 h) or miR-194 inhibitor (200 nm, 96 h) transfected cells (n = 5). The bar diagrams represent relative miRNA-194 contents of miR-control or miR-194 mimic or inhibitor-transfected cells used for western blotting. Results are mean ± s.d. (n = 5), *P < 0.05. (d) miR-194 mimic accentuates, whereas (e) miR-194 inhibitor decreases siSPRY2-induced upregulation of E-cadherin. A representative western blotting of E-cadherin and SPRY2 expression in SPRY2-downregulated SW480 cells or in combination with miR-194 mimic or miR-194 inhibitor transfections (n = 3). The bar diagram represents relative miR-194 contents of miR-194 mimic or inhibitor-transfected cells used for western blotting. Results are mean ± s.d. (n = 3), *P < 0.05. (f) miR-194 transfection decreases cell migration and invasion of HCT116 and SW480 cells in a trans-well assay. Average number of cells from three random microscopic fields per insert were counted, size bar = 200 μm. Results from three independent experiments were analyzed, and data are expressed as mean ± s.d., (n = 3), **P < 0.05. The bar diagram also represents relative miRNA-194 contents of miR-control or miR-194 mimic-transfected cells used in migration and invasion assays. Results are mean ± s.d., (n = 3), *P < 0.05.
Concurrent suppression of SPRY1 and SPRY2 upregulates E-cadherin, epithelial markers and suppresses mesenchymal markers.

SPRY1 has also been implicated with tumorigenesis in prostate and breast cancer. SPRY1 and SPRY2 share a unique highly conserved COOH-terminal cysteine-rich domain. However, the NH2-terminal portion of SPRY protein is less conserved and exhibits only 25–37% identity among the different family members. These sequence differences could be responsible for the functional divergence among the SPRY proteins. We raised the question whether suppression of SPRY1 in colon cancer cells would exhibit a diverse effect on E-cadherin expression. Suppression of SPRY1 also increased E-cadherin expression in both cell lines (Supplementary Figure S10). We further raised the question whether suppression of both SPRY1 and SPRY2 in colon cancer cells would exhibit a diverse effect on mesenchymal/EMT...
markers. To test this hypothesis, we suppressed both SPRY1 and SPRY2 in cancer cells by siRNA method. Concurrent suppression of SPRY1 and SPRY2 also increased E-cadherin expression in HCT116 and SW480 cells (Figures 5a and b). Concurrent suppression accentuated the reduction of EMT markers (Figures 5a and b) as compared with SPRY2 suppression alone (Figure 1e). Further, SPRY1 and SPRY2 downregulation also increased epithelial marker ZO1 and suppressed mesenchymal marker fsp-1 and EMT markers Zeb-1 and SNAIL2 in HCT116 cells (Figure 5a). In SW480 cells, in addition to fsp-1 a significant decrease in mesenchymal markers Vimentin and N-cadherin and upregulation of epithelial protein Occludin was observed (Figure 5b). N-cadherin was not detected in HCT116 cells. Collectively, data indicate that suppression of both SPRY1 and SPRY2 had additional effects that favor epithelial phenotype in colon cancer cells.

Spry1f/f; Spry2f/f MEFs exhibited increased epithelial markers and reduced cell migration

We utilized SPRY1 and SPRY2 floxed mouse to evaluate biological significance of the loss of SPRY1 and SPRY2 in MEFs. CAAG-CreERTMfl/+; Spry1fl/fl; Spry2fl/fl ROSA26lacZ/+ MEF lines (here onwards referred as Spry1fl/fl; Spry2fl/fl) were cultured and treated with tamoxifen in MEF culture medium at 37 °C for 48 h to generate CAAG-CreERTMfl/+; Spry1−/−; Spry2−/−; ROSA26lacZ/+ double mutant cells (here onwards referred as Spry1−/−; Spry2−/−). Addition of tamoxifen resulted in deletion of Spry1 and Spry2 that was confirmed by qRT–PCR and lacZ expression (Figure 5c). A complete recombination and >90% reduction in Spry1 and Spry2 transcripts was noted. Further, LacZ expression was present in >80% of cells after 48 h tamoxifen treatment (Figure 5c). MEFs were further incubated without tamoxifen in complete medium for 48 h, and mRNA contents of epithelial markers were assessed. MEFs exhibit the expression of variety of epithelial cell markers, including cytokeratins 14 and 18 as well as desmoplakin and ZO1.21 E-cadherin was not detected in these cells (data not shown). Spry1−/−; Spry2−/− MEFs demonstrated a significant increase (P < 0.05) in mRNA transcripts of desmoplakin, cytokeratins 14 and 18 when compared with Spry1fl/fl; Spry2fl/fl MEFs (Figure 5d). Further, migration of Spry1−/−; Spry2−/− MEFs across the migration chambers was significantly reduced (58%, P < 0.05) as compared with Spry1fl/fl; Spry2fl/fl MEFs (Figure 5e). Collectively, data indicate that SPRY1 and SPRY2 deletions commit embryonic MEFs to an epithelial status, which is highlighted by the increased expression of epithelial markers desmoplakin and cytokeratin and may be responsible for the decreased cell migration as observed in the current study.

Figure 3. MiR-194 reduces AKT2. (a) miR-194 decreases AKT2 protein levels in cancer cells; a representative western blotting and quantification of AKT2 protein in miR-control or miR-194 mimic-transfected cells (n = 5). The bar diagram represents relative miR-194 contents of miR-control or miR-194 mimic-transfected cells used for western blotting. Results are mean ± s.d., (n = 5), *P < 0.05. (b) SPRY2 suppression decreases AKT2 expression. A representative western blotting of SPRY2 and AKT2 protein expression in HCT116 and SW480 cells transfected with control scrambled siRNA or siRNA SPRY2 (n = 5). (c) Effect of miR-194 on the luciferase activities of wild-type and mutant AKT2 3’UTR reporters; cancer cells were transfected with pcMV miR-empty vector or miR-194 precursor vector (pcMV-miR-194) and pmir-GLO empty vector (Empty Vector) or 3’UTR wild-type AKT2 (pmir-GLO vector-AKT2 3’UTR) or 3’UTR mutant AKT2 (pmir-GLO vector-AKT2 3’UTR mutant) for 48 h. Luciferase activities were determined using a dual luciferase assay. Relative expression of firefly luciferase was standardized to a transfection control. Data represent mean ± s.d. of three independent experiments in triplicate, *P < 0.05. (d) AKT2 suppression increases E-cadherin expression; a representative western blotting and quantification of E-cadherin and AKT2 in HCT116 and SW480 cells transfected with control scrambled siRNA or siRNA AKT2 siRNA (n = 5). Bar diagram represents miR-194 contents of control siRNA or siRNA AKT2 transfected cells. (e) AKT2 lacking 3’UTR transfection reverses siSPRY2-induced upregulation of E-cadherin. A representative western blotting of E-cadherin expression in SW480 cells transfected with siSPRY2 or in combination with AKT2 lacking 3’UTR (n = 3). (f) miR-194 accentuates siAKT2-induced upregulation of E-cadherin. A representative western blotting of E-cadherin expression in SW480 cells transfected with siAKT2 or miR-194 mimics or in combination (n = 3). The bar diagram represents relative miR-194 contents of control or siRNA AKT2 or miR-194 or combination of siAKT2 and miR-194-transfected cells used for western blotting (n = 3). Data represents (one-way analysis of variance) mean ± s.d. of three independent experiments, *P < 0.05.
EMT, a key process contributing to tumor metastasis, is portrayed by the loss of the epithelial marker E-cadherin and increase in EMT-inducing transcription factors. E-cadherin, a cell–cell adhesion molecule, is functionally necessary for epithelial integrity. In CRC, loss of E-cadherin is associated with the loss of tumor differentiation, increased lymph node and distant metastasis. EMT-inducing transcription factors can repress E-cadherin directly or indirectly. Direct repressors include SNAIL superfamily and E-box-binding proteins of ZEB family. Factors such as TWIST and AKT repress E-cadherin transcription indirectly. AKT activation has been shown to induce SNAIL expression, which in turn represses E-cadherin. Further, TWIST transcriptionally upregulates AKT2 and represses E-cadherin expression. These studies clearly indicate that AKT and EMT-inducing transcription factors are interwoven in regulation of E-cadherin expression.

We demonstrated that SPRY2 suppression alters cancer cell morphology from fibroblastoid to epithelial type and decreases cell migration with concomitant increase in E-cadherin expression.
expression and reduction in EMT-inducing transcription factors. Further, ectopic expression of miR-194 also augmented E-cadherin expression and lowered AKT2 expression by targeting 3’UTR of AKT2. In this regard, AKT2 upregulation has been shown to be associated with malignant transformation and EMT in CRC. AKT2 amplification is responsible for decreased apoptosis, increased survival, migration, invasion and metastasis in CRC. An important finding of our study was the inverse expression pattern of AKT2 and E-cadherin in human colorectal carcinomas. Interestingly, in vitro, studies also demonstrated that AKT2 suppression upregulates E-cadherin expression.

We established that concurrent suppression of SPRY1 and SPRY2 may have additional effects in decreasing EMT markers or EMT-inducing transcription factors and thus favoring epithelial phenotype in colon cancer cells. We extended our studies to MEFs that were isolated from the Spry1 and Spry2 floxed mouse. In vitro, deletion of Spry1 and Spry2 in MEFs augmented epithelial markers and decreased cell migration. It is not clear, however, at this point of investigation whether a similar phenotype would be present, in vivo, in colon epithelial cells of this model. In this regard, SPRY2 blocked fibroblast growth factor-induced mesenchymic cell migration to the developing testis in male sex organogenesis. On the contrary, conditional deletion of SPRY1 and SPRY2 reduced motility in the ocular surface epithelial cells that results in ‘EOB’ (eyes open at birth) phenotype.

In summary, our results have identified that suppression of SPRY leads to reduction in EMT and enhancement in a phenotype that favors epithelial features (Figure 5f). Suppression of SPRY upregulates E-cadherin/epithelial markers and suppresses EMT/mesenchymal markers in CRC cell lines. However, different cell lines showed different epithelial and EMT markers changed following SPRY suppression. Colon cancer cell lines differ with respect to many genetic derangements. This is reflected by their different growth rates and susceptibilities to various drugs. It is thus not surprising that two different cell lines will differ in response to alterations in SPRY expression as these cell lines likely also differ in SPRY substrates and SPRY regulators. SPRY2-dependent regulation of E-cadherin is the end-organ effect of reduction of both direct and indirect targets of miR-194. MiRs exert their end-organ effects via direct mRNA targets and by secondary and tertiary effects that accumulate through so-called ‘indirect’ targets. Cancer, a heterogeneous disease, cannot be successfully treated by targeting a single gene of interest. The promising ability of miRs to control several genes associated with a particular cellular pathway therefore may hold the key to therapeutic success. Thus regulation of miR-194 by SPRY2 and suppression of AKT2 and other EMT markers by miR-194 could be considered as a potential anticancer therapeutic strategy. We have earlier established a role of SPRY2 in maintaining oncogenic c-Met expression in CRC. Our findings were recently confirmed and a similar regulation of c-Met by SPRY2 has been reported in non-small cell lung cancer. Together, our studies indicate a role of SPRY in sustaining processes important to malignancy in CRC, and suppression of SPRY may inhibit EMT in CRC patients.

**MATERIALS AND METHODS**

Antibodies and RT-PCR primers

Supplementary Tables 2 and 3 describes antibodies and primers, respectively.

**Cell culture**

Please see Supplementary Material.

**SPRY1 and SPRY2 mutant mouse**

Female mice, between 3 and 4 months, carrying Spry1flox/fox. Spry2flox/fox. ROSA26lacZ/ROS26lacZ were crossed to B6.Cg-Tg (CAG-cre/Esr1)34. MEFs were isolated from (CAAG-CreER, JAX stock number 004453) in which a ubiquitously expressed Cre gene was fused to a tamoxifen-inducible mutant of the estrogen receptor. Cre-mediated recombination was initiated by incubation of MEFs in media containing 1μM tamoxifen, fixed in 1% glutaraldehyde and stained with X-gal as described. A complete method to generate MEFs is explained under Supplementary Material. All procedures were approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin.

**SPRY2 suppression by lentiviral shRNA**

Please see Supplementary Material.

**miR microarray profiling**

RNA from SPRY2 shRNA or control non-silencing shRNA-infected cells were labeled using miRCURY Hy3/Hy5 Power Labeling Kit (Exiqon, Woburn, MA, USA). Hy3/Hy5 fluorescent-labeled RNA samples were hybridized to the miRCURY LNA array (v.9.2) using a hybridization station. The quantified signals (background subtraction) were normalized using the global lowess (Locally Weighted Scatterplot Smoothing) regression algorithm that utilizes within-slide normalization to minimize dye-dependent differences in intensity. Exiqon carried out the miRNA labeling, hybridization and preliminary array analyses. (GEO Repository http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69665).

**RNA isolation**

Please see Supplementary Material.

**Real-time PCR**

Please see Supplementary Material.

**Transfection**

Please see Supplementary Material.

Figure 4. MiR-194 increases E-cadherin association with membrane and an inverse expression pattern of AKT2 with E-cadherin in human CRC. Cancer cells were transfected with miR-control or miR-194 and plated on collagen-coated cover slips. Immunofluorescence confocal microscopy was performed to assess the expression and localization of AKT2 and E-cadherin. MiR-194 transfection significantly increased membrane localization of E-cadherin and partial association of E-cadherin with AKT2 in (a) HCT116 and (b) SW480 cells, (n = 5). The size bar is 20 μm. (c) Human CRC tissue microarrays were used to quantify AKT2 and E-cadherin expression. Tissue microarray contained paraffin-embedded sections from 33 matched pairs (66 samples covering 33 adjacent normal and 33 adenocarcinomas). To quantify immunostaining, images of cross-sections were captured under identical imaging conditions and imported into Image-Pro Plus software. Six regions of interest (ROI) were drawn. The amount of positive immunostaining within each ROI (expressed as positive pixels/mm²) was determined by false color segmentation analysis. Results are mean ± s.d., *P < 0.05. (d) Immunostaining of AKT2 and E-cadherin in three representative adenocarcinomas and adjacent normal tissue. (e) Boxplot charts demonstrating higher E-cadherin and lower AKT2 expression in normal adjacent tissue when compared with adenocarcinomas shown in panel (d). Immunohistochemical results were shown as Integral Optical Density (IOD)/area. Median value of each group is shown as the middle solid line within each box. Top and bottom lines of each box indicate 75th and 25th percentiles, respectively. Trendline connects the mean value of each group. Nonparametric Mann–Whitney U-test is adopted owing to the non-normal distribution of data. Both tests lead to significant differences at P < 0.001.
Figure 5. SPRY1 and SPRY2 suppression in colon cancer cells or deletion of Spry1 and Spry2 in MEFs upregulates epithelial and reduces mesenchymal markers. mRNA transcripts of epithelial (E-cadherin, ZO1 and Occludin) and mesenchymal/EMT (Zeb1, SNAIL2, fsp1, N-cadherin and Vimentin) markers in (a) HCT116 and (b) SW480 cells transfected with control scrambled siRNA or a mixture of SPRY1 (75 nM) and SPRY2 (75 nM) siRNA. Results are mean ± s.d., (n = 5), *P < 0.05. (c) Tamoxifen treatment resulted in deletion of Spry1 and Spry2 that was confirmed by quantitative RT-PCR and lacZ expression, size bar = 500 μm. Results are mean ± s.d., (n = 5), *P < 0.05. (d) Tamoxifen-dependent recombination and deletion of Spry1 and Spry2 in MEFs increases the expression of epithelial markers. mRNA transcripts of des, ZO1, Keratin-14 and Keratin-18 in Spry1−/−;Spry2−/− MEFs. Results are mean ± s.d., (n = 5), *P < 0.05. (e) Deletion of Spry1 and Spry2 in MEFs reduces cell migration in a trans-well migration assay. Average number of cells from three random microscopic high power (HP) fields per insert were counted, size bar = 400 μm. Results from three experiments (n = 3) were analyzed, and data are expressed as mean ± s.d., *P < 0.05. (f) SPRY signaling in cancer cells and MEFs.
REFERENCES

1. Hacohen N, Kramer S, Sutherland D, Hironmi Y, Krasnow MA. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998; 92: 253–263.

2. Leekima OC, Van Achterberg TA, Tsumura Y, Toshima J, Eldering E, Kroes WG et al. Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. Eur J Biochem 2002; 269: 2546–2556.

3. Xu AI, Cooke MP, Ching KA, Hakak Y, Walker JR, Witshire T et al. Large-scale analysis of the human and mouse transcriptomes. Proc Natl Acad Sci USA 2002; 99: 4465–4470.

4. Masoumi-Moghaddam S, Amini A, Morris DL. The developing story of Sprouty and cancer. Cancer Metastasis Rev 2014; 33: 695–720.

5. Holgren C, Dougherty U, Edvin F, Cerasi D, Taylor I, Fichera A et al. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty-c-Met upregulation in human colonic adenocarcinomas. Oncogene 2010; 29: 5241–5253.

6. Ordonez-Moran P, Jirisch A, Barbacchiano A, Chiozzi L, Tenbaum S, Landolfi S et al. Sprouty2 is a beta-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer. Oncogene 2014; 33: 1975–1985.

7. Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PJ, Yeh KT et al. Deregressed expression of sprouty2 and microRNA-21 in human colon cancer: correlation with the clinical stage of the disease. Cancer Biol Ther 2011; 11: 111–121.

8. Rhodes DR, Yu J, Shrank W, Spitz D, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1–6.

9. Barbacchiano A, Ordonez-Moran P, Garcia JM, Sanchez A, Pereira F, Larriba MJ et al. SPROUTY-2 and E-cadherin regulate reciprocally and dictate colon cancer cell tumorigenicity. Oncogene 2010; 29: 4800–4813.

10. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K et al. Different expression gene signatures between colorectal cancers with and without KRAS mutations: crosstalk between the KRAS pathway and other signalling pathways. Eur J Cancer 2011; 47: 1946–1954.

11. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol 2005; 17: 559–564.

12. Plissieux A, Brablitz T, Caramel J. Oncogenic roles of EMT-inducing transcription factors. Nat Cell Biol 2014; 16: 488–494.

13. Natalwala A, Spychal R, Tselepis C. Epithelial-mesenchymal transition mediated tumorigenesis in the gastrointestinal tract. World J Gastroenterol 2008; 14: 3792–3797.

14. Diaz-Lopez A, Moreno-Bueno G, Cano A. Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. Cancer Manag Res 2014; 6: 205–216.

15. Kumarswamy R, Volkman I, Thum T. Regulation and function of microRNA-21 in health and disease. RNA Biol 2011; 8: 706–713.

16. Tazawa H, Kagawa S, Fujivara T. MicroRNAs as potential target gene in cancer gene therapy of gastrointestinal tumors. Expert Opin Biol Ther 2011; 11: 145–155.

17. Buchan JR, Parker R. Molecular biology. The two faces of miRNA. Nature 2007; 318: 1877–1878.

18. Li XY, Zhou X, Rowe RG, Hu Y, Schlaepfer DD, Ilic D et al. MicroRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation in human tissues. Genome Res 2004; 14: 1193–1208.

19. Villagrasa P, Diaz VM, Vinas-Castells R, Peiro S, Del Valle-Perez B, Dave N et al. Akt2 interacts with Snail1 in the E-cadherin promoter. Oncogene 2012; 31: 4022–4033.

20. Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by microRNA-215. Cancer Res 2014; 74: 605–616.

21. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.

22. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I et al. MicroRNA-21 expression is regulated by HNF-1alpha during intestinal epithelial cell differentiation. Cell Signal 2013; 25: 1711–1719.

23. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834–838.

24. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I et al. MicroRNA-21 expression is regulated by HNF-1alpha during intestinal epithelial cell differentiation. Cell Signal 2013; 25: 1711–1719.
29 Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res 2008; 28: 3815–3826.

30 Grille S, Bellacosa A, Larue L. [Regulation of E-cadherin by the Akt protein kinase B]. J Soc Biol 2004; 198: 375–378.

31 Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007; 67: 1979–1987.

32 Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 20315–20320.

33 Chi L, Itaranta P, Zhang S, Vainio S. Sprouty2 is involved in male sex organogenesis by controlling fibroblast growth factor 9-induced mesonephric cell migration to the developing testis. Endocrinology 2006; 147: 3777–3788.

34 Hick AC, Delmarcelle AS, Bouquet M, Klotz S, Copetti T, Forez C et al. Reciprocal epithelial/endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation. Dev Biol 2013; 381: 227–240.

35 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603–607.

36 Acunzo M, Romano G, Palmieri D, Lagana A, Garofalo M, Balatti V et al. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci USA 2013; 110: 8573–8578.

37 Basson MA, Akbulut S, Watson-Johnson J, Simon R, Carroll TJ, Shakya R et al. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. Dev Cell 2005; 8: 229–239.

38 Shim K, Minowada G, Coling DE, Martin GR. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. Dev Cell 2005; 8: 553–564.

39 Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 1999; 21: 70–71.

40 Hayashi S, McMahon AP. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev Biol 2002; 244: 305–318.

41 Khare S, Holgren C, Samarel AM. Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase Shp2. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1100–G1112.

42 Khare S, Bissonnette M, Wall R, Skarosi S, Boss GR, von Lintig FC et al. 1,25-dihydroxyvitamin D3 but not TPA activates PLD in Caco-2 cells via pp60 (c-src) and RhoA. Am J Physiol 1999; 276: G1005–G1015.

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)